The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia

INTRODUCTION: Glucagon-like peptide-1 (GLP-1) receptor agonists represent a class of treatments for type 2 diabetes that offer multifactorial benefits, including glycemic control, weight loss and low hypoglycemia risk. Once-weekly semaglutide is a novel GLP-1 analog that has been associated with imp...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Adv Ther
Auteurs principaux: Malkin, Samuel J. P., Russel-Szymczyk, Monika, Psota, Marek, Hlavinkova, Lucia, Hunt, Barnaby
Format: Artigo
Langue:Inglês
Publié: Springer Healthcare 2019
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6822857/
https://ncbi.nlm.nih.gov/pubmed/31168765
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-019-00965-y
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires